Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
228 hedge funds and large institutions have $2.14B invested in Genomic Health, Inc. in 2018 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 77 increasing their positions, 66 reducing their positions, and 27 closing their positions.
104% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 27
17% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 66
13% more funds holding
Funds holding: 201 → 228 (+27)
6% less capital invested
Capital invested by funds: $2.29B → $2.14B (-$143M)
29% less call options, than puts
Call options by funds: $2.97M | Put options by funds: $4.21M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$25.3M |
| 2 |
CRCP
Copper Rock Capital Partners
Boston,
Massachusetts
|
+$20.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$17.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.6M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$143M |
| 2 |
Millennium Management
New York
|
-$21.4M |
| 3 |
Man Group
London,
United Kingdom
|
-$10.6M |
| 4 |
SIM
Spark Investment Management
New York
|
-$7.06M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.57M |
GHDX Hedge Fund Activity: Q4 2018 in Review
228 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2018, worth a combined $2.14B — down 6.3% from $2.29B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new GHDX positions and 27 closed out — a net gain of 28 holders — while 77 added to existing stakes and 66 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $25.3M. The largest seller was Baker Bros. Advisors, cutting an estimated $143M.
- 228 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2018, up from 201 in Q3 2018.
- Funds reported $2.14B of Genomic Health, Inc. stock for Q4 2018, down 6.3% quarter-over-quarter.
- 55 funds opened new Genomic Health, Inc. positions in Q4 2018 and 27 closed out, a net change of +28 holders.
- The largest Genomic Health, Inc. buyer in Q4 2018 was OppenheimerFunds, an estimated $25.3M added.
- The largest Genomic Health, Inc. seller in Q4 2018 was Baker Bros. Advisors, an estimated $143M sold.
Based on aggregated 13F filings for Q4 2018.